Xeris Pharmaceuticals (XERS) PT Lowered to $9 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts XERS Hot Sheet
Price: $10.35 +1.77%
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Jefferies analyst David Steinberg lowered the price target on Xeris Pharmaceuticals (NASDAQ: XERS) to $9.00 (from $11.00) while maintaining a Buy rating.
You May Also Be Interested In
- Hagerty Inc. (HGTY) PT Raised to $20 at Oppenheimer
- Tower Semiconductor (TSEM) PT Lowered to $235 at Stifel
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
